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OBJECTIVES: To assess the health economic impact of oral nutritional supplements 
(ONS), being a medical nutrition product, in residential care from the society perspec-
tive in Germany in 2009. METHODS: This health economic analysis is based on a 
comparison of the use of ONS versus “no ONS” in residential care patients who are 
eligible for ONS due to disease-related malnutrition (DRM). The costs of the two 
treatment strategies ONS versus “no ONS” were assessed using a linear decision 
analytic model reﬂecting costs related with DRM. The model structure allowed for 
differences in costs for ONS and cost of care. Clinical probabilities and resource 
utilization were based on clinical trials and published literature; cost data were from 
ofﬁcial price tariffs. RESULTS: The use of ONS reduces the total costs from 3 16,617 
to 3 15,453, which corresponds with a 31,164 cost savings per residential care patient. 
The additional costs of ONS are more than balanced by a reduction on cost of care. 
Sensitivity analyses were performed on all parameters, including cost of care and 
improvement of DRM. These results showed that the use of ONS in all sensitivity 
analyses leads to cost savings. CONCLUSIONS: This health economic analysis shows 
that the use of ONS in residential care patients is a cost-effective treatment in Germany 
and is dominant over standard care without ONS: it leads to cost savings and a higher 
effectiveness.
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OBJECTIVES: To assess the economic impact of oral nutritional supplements (ONS), 
being a medical nutrition product, in elderly patients in the ambulatory setting from 
the society perspective in Germany in 2009. METHODS: This health economic analy-
sis is based on a comparison of the use of ONS versus “no ONS” in elderly (>65 
years) patients in the ambulatory setting who are eligible for ONS due to disease-
related malnutrition (DRM). The costs of the two treatment strategies ONS versus 
“no ONS” were assessed using a linear decision analytic model reﬂecting costs related 
with DRM. The model structure allowed for differences in costs for ONS, consulta-
tions and hospitalization costs. Clinical probabilities and resource utilization were 
based on clinical trials and published literature; cost data were from ofﬁcial price 
tariffs. RESULTS: The use of ONS reduces the total costs from 31376 to 31197, which 
corresponds with a 3179 cost savings per patient. The additional costs of ONS are 
more than balanced by a reduction of consultations and hospitalization. Sensitivity 
analyses were performed on all parameters, including cost of hospitalization and 
improvement of DRM. These results showed that the use of ONS in all sensitivity 
analyses leads to cost savings. The use of ONS would lead to an annual cost saving 
of 3344 million based on the number of 1.9 million malnourished elderly in Germany. 
CONCLUSIONS: This health economic analysis shows that the use of ONS in eligible 
elderly patients in the ambulatory setting leads to a positive economic impact in 
Germany.
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OBJECTIVES: To develop and validate a patient-reported outcome measure for elbow 
surgery. METHODS: A questionnaire was created following semi-structured inter-
views with 18 patients being treated for elbow problems to determine candidate 
questions. These 18 questions were then prospectively tested, pre- and again at 6 
months post-surgery, on 104 patients undergoing a variety of surgical treatments for 
elbow problems. Assessment of test/re-test reliability involved repeated OES comple-
tion, at home, 2 days later. Candidate questions were excluded if they showed high 
ceiling or ﬂoor effects, or if they cross-loaded to more than one domain. Underlying 
factor structure, dimensionality, internal and test retest reliability, construct validity 
and responsiveness of the questionnaire items were assessed in relation to the: 1) Mayo 
Elbow Performance Score (MEPS) clinical scale; 2) Disabilities of the Arm, Shoulder 
and Hand (DASH) questionnaire; and 3) SF-36 general health survey. RESULTS: A 
total of 75% of patients were followed-up. Six candidate questions were excluded due 
to ceiling effect, cross loading or disordered response in Rasch analysis. A ﬁnal 12-item 
questionnaire resulted, consisting of 3 unidimensional domains/scales: ‘Elbow Func-
tion’, ‘Pain’, ‘Social-Psychological’. Internal reliability (Cronbach’s alpha) for the 3 
OES domains were optimal: Pain 0.89, Elbow function 0.90, Social-psychological 
0.84. Test-retest reliability, (intra-class correlation coefﬁcient), was good for all three 
domains (0.98; 0.90; 0,87). The OES showed high convergent correlation with the 
DASH and MEPS, with the exception of the social-psychological with the MEPS, 
which showed moderate correlation; correlation with related domains of the SF-36 
was high. Divergent validity was conﬁrmed by moderately low correlation with the 
general and mental health domains of the SF-36. Responsiveness was good, with effect 
sizes of >1.0 for the OES pain and social-psychological domains and for the MEPS; 
0.80 for OES function and −0.74 for the DASH. CONCLUSIONS: The 12-question 
OES has good measurement properties in the context of elbow surgery.
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OBJECTIVES: The purpose of this study was to examine the incidence of bleeding-
related complications and blood product transfusions and their impact on hospital 
length of stay (LOS) and total cost in various inpatient surgical cohorts. METHODS: 
A retrospective analysis was conducted using Premier’s Perspective hospital database. 
Patients who had an inpatient procedure within a specialty of interest (cardiac, vas-
cular, non-cardiac thoracic, solid organ, general, reproductive organ or knee/hip 
replacement) during 2006–2007 were identiﬁed based on ICD-9-CM procedure codes. 
For each specialty, the rate of bleeding-related complications (including bleeding event, 
interventions to control for bleeding and blood product transfusions) were examined, 
and hospital costs and length of stay (LOS) were compared between surgeries with 
versus without bleeding-related complications. Incremental costs were estimated using 
a multivariate analysis adjusting for demographics, hospital characteristics and other 
baseline characteristics. RESULTS: A total of 103,922 cardiac, 216,380 vascular, 
142,698 non-cardiac thoracic, 45,824 solid organ, 362,797 general, 12,271 reproduc-
tive organ and 247,287 knee/hip replacement surgeries were identiﬁed. Overall, the 
rate of bleeding-related complications was 42.2% and ranged from 27.5% to 47.5% 
for general and cardiac surgeries, respectively. Incremental LOS associated with 
bleeding-related complications or transfusions across all specialties averaged 5.5 days 
and ranged from 1.3 to 9.6 days for knee/hip replacement and non-cardiac thoracic 
surgeries, respectively. The incremental cost per hospitalization associated with bleed-
ing-related complications was highest for vascular ($15,296) followed by solid organ 
($14,072), non-cardiac thoracic ($13,715), cardiac ($10,279), general ($4,364), repro-
ductive organ ($8,200) and knee/hip replacement ($3,025). CONCLUSIONS: This 
study demonstrates the high incidence of and increased economic burden associated 
with bleeding-related complications and transfusions among inpatient surgical 
patients. Given the high burden, implementation and economic impact assessment of 
blood conservation strategies should be further evaluated.
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OBJECTIVES: Transplantation requires the use of immunosuppressive agents (ISAs) 
to prevent acute rejection and chronic allograft dysfunction. The purposes of this study 
were to analyze ISA utilization and expenditure trends in the U.S. Medicaid market. 
METHODS: Study ISAs included azathioprine (AZA), mycophenolate mofetil (MMF), 
cyclosporine (CsA), sirolimus (SIR), tacrolimus (TAC), antithymocyte globulin, and 
monoclonal antibodies. The data source was the national summary ﬁle of Medicaid 
outpatient drug utilization data for the years 1991 to 2007. A retrospective, descriptive 
trend analysis was conducted to assess the yearly trends in number of prescriptions, 
reimbursement, reimbursement per prescription, and prescription and reimbursement 
market shares. RESULTS: The oral ISA prescriptions and reimbursements increased, 
respectively, from 162,000 and $34 million in 1991 to 719,550 and $251 million in 
2005. Meanwhile, the prescriptions and reimbursements of ISA induction antibodies 
increased from 12 and $9,356 in 1991 to 435 and $548,652 in 2005. Utilization and 
reimbursement fell in 2006 and 2007. Among oral ISAs, the prescription market share 
of CsA was 65% in 1991, increased to 97% in 1994, and gradually decreased to 15% 
in 2007, while the market share of AZA fell from 35% in 1991 to 1% in 1994, and 
ranged from 13%–30% over the period 1996–2007. Utilization of both TAC and 
MMF has increased since their introduction; these drugs have dominated the market 
since 2004. The average per-prescription reimbursement for AZA and CsA has 
decreased since 1998, while that for MMF, SIR and TAC has increased. CONCLU-
SIONS: A signiﬁcant increase in Medicaid expenditure on ISAs may be due to the 
increased number of transplant recipients and increased ISA prices over time. TAC 
and MMF dominated the oral ISA market because of their strong efﬁcacy and safety 
proﬁles. A signiﬁcant drop in utilization during 2006–2007 was related to the intro-
duction of Medicare Part D.
